Exploring the Complex Nature of IgA Nephropathy

IgA nephropathy (IgAN) is a challenging disease to manage due to its heterogeneous presentation, unpredictable progression, and variable response to therapy. Patients may range from being asymptomatic with isolated hematuria to experiencing progressive kidney dysfunction leading to end-stage kidney disease. This clinical variability makes risk stratification and treatment decision-making difficult. In addition, disease progression often occurs slowly over many years, complicating early identification of patients who would benefit most from intervention. The absence of reliable biomarkers to accurately predict prognosis and treatment response further adds to the complexity. Together, these factors underscore the need for improved tools to personalize care and optimize long-term outcomes for patients with IgAN.